Insider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells 2,775 Shares of Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Andrew Callos sold 2,775 shares of Cytokinetics stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $44.38, for a total value of $123,154.50. Following the completion of the sale, the executive vice president now directly owns 34,888 shares of the company’s stock, valued at approximately $1,548,329.44. This trade represents a 7.37 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Andrew Callos also recently made the following trade(s):

• On Friday, March 14th, Andrew Callos sold 100 shares of Cytokinetics stock. The shares were sold at an average price of $45.00, for a total transaction of $4,500.00.
• On Thursday, March 6th, Andrew Callos sold 3,341 shares of Cytokinetics stock. The shares were sold at an average price of $43.27, for a total transaction of $144,565.07.

Cytokinetics Price Performance

CYTK stock opened at $43.28 on Wednesday. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28. Cytokinetics, Incorporated has a one year low of $40.53 and a one year high of $75.71. The stock has a market cap of $5.12 billion, a PE ratio of -8.04 and a beta of 0.95. The firm has a 50 day simple moving average of $46.15 and a two-hundred day simple moving average of $50.13.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.03. The business had revenue of $16.93 million during the quarter, compared to analysts’ expectations of $14.26 million. On average, analysts predict that Cytokinetics, Incorporated will post -5.24 EPS for the current fiscal year.

Institutional Investors Weigh In On Cytokinetics

Institutional investors have recently made changes to their positions in the business. Jones Financial Companies Lllp boosted its stake in shares of Cytokinetics by 189.8% in the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 374 shares in the last quarter. Centricity Wealth Management LLC purchased a new stake in shares of Cytokinetics in the 4th quarter valued at $29,000. AlphaQuest LLC boosted its stake in shares of Cytokinetics by 113,500.0% in the 4th quarter. AlphaQuest LLC now owns 1,136 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 1,135 shares in the last quarter. J.Safra Asset Management Corp boosted its stake in shares of Cytokinetics by 62.1% in the 4th quarter. J.Safra Asset Management Corp now owns 1,751 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 671 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in shares of Cytokinetics by 85.8% in the 4th quarter. Blue Trust Inc. now owns 1,823 shares of the biopharmaceutical company’s stock valued at $86,000 after purchasing an additional 842 shares in the last quarter.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on CYTK shares. HC Wainwright reissued a “buy” rating and issued a $120.00 price target on shares of Cytokinetics in a research report on Friday, February 28th. Needham & Company LLC reissued a “buy” rating and issued a $72.00 price target on shares of Cytokinetics in a research report on Thursday, February 6th. Royal Bank of Canada boosted their price target on shares of Cytokinetics from $80.00 to $82.00 and gave the company an “outperform” rating in a research report on Wednesday, December 18th. JMP Securities reissued a “market outperform” rating and issued a $78.00 price target on shares of Cytokinetics in a research report on Friday, February 7th. Finally, Evercore ISI raised shares of Cytokinetics to a “strong-buy” rating in a report on Friday, February 7th. Two investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $82.00.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.